Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
153
datasets available to search
ShareScore release 0.9.0
Dataset results
153 results for “Bacteriophages”
S-SAD data set used for solving the structure of esterase vb_24B_21 from Shiga toxin-encoding bacteriophage phi24B; PDB id 6YP6
<p>S-SAD data set used for solving the structure of esterase vb_24B_21 from Shiga toxin-encoding bacteriophage phi24B</p> <p>Data were measured at Diamond I02 on February 1, 2014</p> <p>PDB id is 6YP6</p> <p> </p>
Data from: Modification of Escherichia coli–bacteriophage interactions by surfactants and antibiotics in vitro
Although experiments indicate that the abiotic environment plays an important role in bacterial interactions with their parasitic viruses (bacteriophages or phages), it is not yet clear how exposure to compounds present in nature alters the impact of phages on bacterial growth and evolution. To address this question, we exposed Escherichia coli K12 MG1655, in combination with three lytic phages, to various substances that natural and clinical microbial populations are likely to encounter: bile salts (present in mammalian gastrointestinal tracts), sodium dodecyl sulfate (SDS, a common surfactant in cleaning and hygiene products) and four antibiotics (present at variable concentrations in natural and clinical environments). Our results show that bile salts and SDS can reduce the detrimental effect of phages on bacterial growth. In some cases these compounds completely mitigated any negative effects of phages on bacterial growth and consequently bacteria did not evolve resistance to phages in these conditions. The proportional effects of phages were unaffected by antibiotics in most combinations, excepting three cases of phage-drug synergy. These results suggest that accounting for interactions between phages and environmental factors such as surfactants and antibiotics will improve understanding of both bacterial growth and resistance evolution to phages in vivo and in nature.
Data from: Top-down effects of a lytic bacteriophage and protozoa on bacteria in aqueous and biofilm phases
Lytic bacteriophages and protozoan predators are the major causes of bacterial mortality in natural microbial communities, which also makes them potential candidates for biological control of bacterial pathogens. However, little is known about the relative impact of bacteriophages and protozoa on the dynamics of bacterial biomass in aqueous and biofilm phases. Here, we studied the temporal and spatial dynamics of bacterial biomass in a microcosm experiment where opportunistic pathogenic bacteria Serratia marcescens was exposed to particle-feeding ciliates, surface-feeding amoebas, and lytic bacteriophages for 8 weeks, ca. 1300 generations. We found that ciliates were the most efficient enemy type in reducing bacterial biomass in the open water, but least efficient in reducing the biofilm biomass. Biofilm was rather resistant against bacterivores, but amoebae had a significant long-term negative effect on bacterial biomass both in the open-water phase and biofilm. Bacteriophages had only a minor long-term effect on bacterial biomass in open-water and biofilm phases. However, separate short-term experiments with the ancestral bacteriophages and bacteria revealed that bacteriophages crash the bacterial biomass dramatically in the open-water phase within the first 24 h. Thereafter, the bacteria evolve phage-resistance that largely prevents top-down effects. The combination of all three enemy types was most effective in reducing biofilm biomass, whereas in the open-water phase the ciliates dominated the trophic effects. Our results highlight the importance of enemy feeding mode on determining the spatial distribution and abundance of bacterial biomass. Moreover, the enemy type can be crucially important predictor of whether the rapid defense evolution can significantly affect top-down regulation of bacteria.
The enigmatic epitranscriptome of bacteriophages: putative RNA modifications in viral infections
<p>Supplementary table S1 to: The enigmatic epitranscriptome of bacteriophages: putative RNA modifications in viral infections<br>Pozhydaieva, N.*, Wolfram-Schauerte, M.*, Keuthen, H., & Höfer, K. (2024). Current Opinion in Microbiology, 77, 102417. https://doi.org/10.1016/j.mib.2023.102417</p>
Bacteriophage Therapy in Tonsillitis
ClinicalTrials.gov study NCT04682964. IPD Sharing: YES. Countries: 1. Publications: 0.
Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis
ClinicalTrials.gov study NCT05182749. IPD Sharing: NO. Countries: 1. Publications: 0.
Bacteriophage Therapy in Patients With Prosthetic Joint Infections
ClinicalTrials.gov study NCT04787250. IPD Sharing: NO. Countries: 1. Publications: 0.
Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection
ClinicalTrials.gov study NCT05948592. IPD Sharing: NO. Countries: 2. Publications: 0.
Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection
ClinicalTrials.gov study NCT06814756. IPD Sharing: NO. Countries: 1. Publications: 0.
Bacteriophage Effects on Pseudomonas Aeruginosa
ClinicalTrials.gov study NCT01818206. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis
ClinicalTrials.gov study NCT05177107. IPD Sharing: NO. Countries: 1. Publications: 0.
Prevalence of Faecal Bacteriophage in Patients With Digestive Symptoms
ClinicalTrials.gov study NCT06524791. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis
ClinicalTrials.gov study NCT06870409. IPD Sharing: YES. Countries: 1. Publications: 0.
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
ClinicalTrials.gov study NCT05010577. IPD Sharing: NO. Countries: 5. Publications: 0.
BacterioPHAGE for Gastrointestinal Health 2 Study
ClinicalTrials.gov study NCT04511221. IPD Sharing: NO. Countries: 1. Publications: 0.
Bacteriophage Therapy in Patients With Urinary Tract Infections
ClinicalTrials.gov study NCT04287478. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
ClinicalTrials.gov study NCT06456424. IPD Sharing: NO. Countries: 1. Publications: 0.
Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)
ClinicalTrials.gov study NCT05269134. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)
ClinicalTrials.gov study NCT01617122. IPD Sharing: Not stated. Countries: 1. Publications: 0.
BActeriophages To Treat Liver Disease Eliminating Harmful Bacteria (BATTLE)
ClinicalTrials.gov study NCT05618418. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.